Low urgency

FDA Expands Sunscreen Options for the First Time in 20 Years

Detected July 27, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

FDA adds bemotrizinol to permitted sunscreen active ingredients, expanding options for the first time in 20 years.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 27, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: None; effective immediately upon publication.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FDA added bemotrizinol to the list of permitted sunscreen active ingredients (21 CFR 352.10).

Who it affects

Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)

What you must do

Review new ingredient for potential product development or reformulation; no immediate compliance action needed.

Deadline

None; effective immediately upon publication.

Source: http://www.fda.gov/news-events/press-announcements/fda-expands-sunscreen-options-first-time-20-years

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)